The company stated that activities at its facilities situated at Plot Nos. 18 and 19 in the PHARMEZ Pharmaceutical Special Economic Zone, Village Matoda, Sarkhej Bawla, Ahmedabad, were paused as a precaution due to water accumulation.
Piramal Pharma confirmed that all staff, including contract personnel, at the affected sites are safe.
ALSO READ | Piramal Pharma receives USFDA EIR for US facility; inspection closed with VAI
The company has begun assessing the conditions of the facilities to ensure a safe and systematic resumption of operations. The potential impact on assets and operations is currently being evaluated.
Operations are anticipated to gradually normalize over the next few days, depending on weather improvements, according to the company.
Piramal Pharma also noted that the assets at the affected facilities are well-protected under the company’s insurance policies. These facilities contribute to less than 3% of its consolidated revenue.
It stated that further updates will be provided regarding any material developments or financial implications as necessary.
ALSO READ | Piramal Pharma shares recover from lows, surge 3% after Co affirms FY26 guidance
Earlier this April, Piramal Pharma projected growth for the financial year 2026-27 (FY27) following a transitional 2025-26 (FY26), with momentum driven by rising demand in its contract development and manufacturing (CDMO) segment and new product launches, Chairperson Nandini Piramal stated.
She remarked that FY26 was affected by external factors such as macroeconomic volatility and product destocking.
Piramal noted an improved outlook with stronger demand signals. “We expect biopharma funding to have increased, leading to a rise in RFPs and order inflows,” she mentioned, adding that the company is finishing FY26 with enhanced momentum.
She projected growth for the upcoming year, stating, “We are guiding for growth in the early to mid-teens… and EBITDA may outpace revenue growth,” she indicated.
ALSO READ | Biosecure Act opens new CDMO opportunity for India, says Piramal Pharma chairperson
The CDMO segment is witnessing heightened activity, with US biotech funding increasing significantly in the latter half of FY26, which has resulted in better order visibility. The company reported that commercial product growth remains robust, even when excluding the effects of a single large product.
Shares of Piramal Pharma Ltd closed at ₹181.65, rising by ₹0.80, or 0.44%, on the BSE.
